Adequate clinical evidence have proven the efficiency of Baricitinib in improving inflammation and joint deformity in RA patients who poorly respond to csDMARDs or bDMARDs. 1,2 Eli Lilly and Docplexus have organized an interactive Webinar on 12 th November 2019 at 2:00 pm. In this webinar session, Dr. S. Ramesh , Dr. Milind Ghare , and Dr.
Sundeep Upadhyaya will discuss their experiences with a year's journey of Baricitinib in clinical practice. Agenda: We invite you to submit your questions which will be answered by the speakers at the end of the session. Reference Emery P, Blanco R, Cocco JM, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD open. 2017 Mar…
